If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

EKF Diagnostics Progressing Well With Kidney POC Platform Development

Tue, 19th Nov 2013 10:56

LONDON (Alliance News) - EKF Diagnostics Holdings said Tuesday it is progressing well with the development of a Point of Care platform for Acute Kidney Injury, with testing on clinical samples set to commence in early 2014.

Testing is the next phase in the development which has been undertaken with Carclo Diagnostic Solutions. The platform is being developed as an alternative to standard lateral flow testing as a device to detect Acute Kidney Injury.

The firm said that testing and an assay based on Carclo's micropoc-pro platform should be complete by mid-2014.

Share in EKF were up 1.57% at 33.0 pence per share Tuesday morning. Carclo shares were trading down 4.89% at 331 pence per share.

By Alice Attwood; aliceattwood@alliancenews.com; @AliceAtAlliance

Copyright © 2013 Alliance News Limited. All Rights Reserved.

Carclo Ekf Diagnostics

Shares in this article

Related News

EARNINGS: Carclo beats mid-term targets as annual profit surges
1 day ago

EARNINGS: Carclo beats mid-term targets as annual profit surges

(Alliance News) - The following is a round-up of earnings reports by London-listed companies, issued on Wednesday and Tuesday and not separately repor...

LONDON MARKET MIDDAY: FTSE 100 falls as Iran uncertainty returns
1 day ago

LONDON MARKET MIDDAY: FTSE 100 falls as Iran uncertainty returns

(Alliance News) - Stock prices in London were lower at midday on Wednesday, as renewed uncertainty about potential talks between the US and Iran weigh...

Market News Babcock + 6 more shares
WINNERS & LOSERS: Shearwater gets contract boost; Carclo falls
1 day ago

WINNERS & LOSERS: Shearwater gets contract boost; Carclo falls

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Wednesday.